Keyphrases
Post-transplantation Cyclophosphamide (PTCy)
100%
Acute Myeloid Leukemia
87%
Confidence Interval
69%
Nonmyeloablative
37%
Myelodysplastic Syndrome
30%
Graft-versus-host Disease Prophylaxis
29%
Myeloablative Conditioning
29%
Transplantation
28%
Overall Survival
28%
Allogeneic Blood or Marrow Transplantation
28%
Hypomethylating Agents
28%
Peripheral Blood
28%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
27%
Risk Factors
27%
HLA Matching
27%
Graft-versus-host Disease (GvHD)
26%
Relapse-free Survival
26%
Hazard Ratio
25%
High Dose
25%
Mantle Cell Lymphoma
25%
Myeloproliferative Neoplasms
25%
Retinoids
25%
Non-relapse Mortality
23%
Mismatched Related Donor
18%
Blood or Marrow Transplantation
18%
CYP26
18%
FMS-like Tyrosine Kinase 3 (FLT3)
18%
Complete Remission
17%
Bone Marrow Microenvironment
15%
Single-center Experience
15%
Relapsed or Refractory
15%
Graft Failure
15%
Intensive Chemotherapy
15%
Graft Source
15%
Bone Marrow
14%
Donor Age
14%
Cyclophosphamide
14%
Primary Graft Dysfunction
13%
All-trans Retinoic Acid
12%
Acute Lymphoblastic Leukemia
12%
SF3B1
12%
High-dose Therapy
12%
Risk Classification
12%
European LeukemiaNet
12%
IDH mutation
12%
Phase 1 Study
12%
FLT3 mutation
12%
Allogeneic Transplantation
12%
Cancer Treatment
12%
Mis-splicing
12%
Medicine and Dentistry
Cyclophosphamide
96%
Acute Myeloid Leukemia
83%
Disease
49%
Overall Survival
41%
Drug Megadose
37%
Graft Versus Host Reaction
33%
Acute Myelogenous Leukemia
33%
Hazard Ratio
30%
Transplantation
27%
Prophylaxis
27%
Recurrence Free Survival
26%
Nonmyeloablative Conditioning
26%
Mantle Cell Lymphoma
25%
Cumulative Incidence
18%
Myelodysplastic Syndrome
15%
Hypomethylating Agent
14%
Cancer Treatment
12%
Systolic Function
12%
Hepatitis B Virus
12%
Cell Transplantation
12%
Allotransplantation
12%
Hematopoietic Stem Cell
12%
Ejection Fraction
12%
Chronic Myelomonocytic Leukemia
12%
Myelofibrosis
12%
Autoimmune Disease
12%
Hepatitis B
12%
Non-Hodgkin Lymphoma
12%
Peripheral T-Cell Lymphoma
12%
Stem Cell Transplant
12%
Acute Lymphoblastic Leukemia
12%
Myeloproliferative Neoplasm
12%
Sulfhemoglobinemia
12%
Venetoclax
12%
Peripheral Blood Stem Cell Transplantation
12%
Ontogeny
12%
Propensity Score Matching
12%
Retinoid
12%
Atypical Hemolytic Uremic Syndrome
12%
Hepatocellular Carcinoma
12%
HLA Matching
12%
Midostaurin
12%
Chronic Graft Versus Host Disease
12%
Whole Body Radiation
11%
Heart Failure with Reduced Ejection Fraction
10%
Myelodysplastic Syndrome
10%
Spontaneous Remission
9%
Doxorubicin
9%
Vincristine
9%
Rituximab
9%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
58%
Disease
52%
Cyclophosphamide
37%
Retinoid
25%
Graft Versus Host Reaction
24%
Overall Survival
20%
Remission
15%
Malignant Neoplasm
15%
Nonhodgkin Lymphoma
14%
Mantle Cell Lymphoma
12%
Heart Failure with Reduced Ejection Fraction
12%
Receptor
12%
Autoimmune Disease
12%
Chronic Myelomonocytic Leukemia
12%
Follicular Lymphoma
12%
Myeloproliferative Neoplasm
12%
Venetoclax
12%
Solid Malignant Neoplasm
12%
Hematologic Disease
12%
CYP3A4
12%
Myelofibrosis
12%
Chronic Graft Versus Host Disease
11%
Recurrence Free Survival
11%
Clinical Trial
10%
Myelodysplastic Syndrome
10%
Cytochrome P450
10%
Heart Failure
10%
Retinoic Acid
8%
Genetic Disorder
8%
Lung Cancer
7%
Prostate Cancer
7%
Breast Cancer
7%
Acute Graft Versus Host Disease
7%
Promyelocytic Leukemia
6%
Leukemia
6%
Cytokine Release Syndrome
6%
Genetic Risk
5%
Graft Failure
5%
Inflammatory Disease
5%
Drug Resistance
5%
Systolic Dysfunction
5%
Adverse Event
5%
Pharmacodynamics
5%
Hypertriglyceridemia
5%
Chemotherapy
5%
Hematologic Malignancy
5%